Shots:
- The EC has approved Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection in pts (≥3yrs.) with compensated liver disease (with or without cirrhosis)
- Approval was based on the P-III (M20-350) trial assessing Maviret (QD, PO) in pts (≥12yrs.) with acute HCV infection, enrolling 286 treatment-naïve adults across 70 locations globally
- Trial met its 1EP with 96.2% pts achieving SVR12 in the ITT population & its key 2EP with 100% of pts achieving SVR12 in the modified ITT-virologic failure population. No virologic failures or relapses occurred, & post-treatment reinfection was reported in 0.7% pts
Ref: PRnewswire | Image: AbbVie | Press Release
Related News: AbbVie’s Aquipta Receives EC Approval for Acute Migraine Treatment
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
